INCSHR 1210

Drug Profile

INCSHR 1210

Alternative Names: HR-301210; INCSHR1210; SHR1210

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Hepatocellular carcinoma
  • Phase II Liver cancer
  • Phase I/II Hodgkin's disease; Solid tumours
  • Phase I Breast cancer; Malignant melanoma; Nasopharyngeal cancer

Most Recent Events

  • 08 Sep 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 23 Aug 2017 Phase-I/II clinical trials in Hodgkin's disease (Combination therapy, In adolescents, In adults, In children, In the elderly, Second-line therapy or greater, Refractory metastatic disease) in China (IV) before August 2017 (NCT03250962)
  • 23 Aug 2017 Phase-I/II clinical trials in Hodgkin's disease (In children, In adolescents, In adults, In the elderly, Monotherapy, Second-line therapy or greater, Refractory metastatic disease) in China (IV) before August 2017 (NCT03250962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top